Clinical Trials Logo
  1. Home
  2. Compensated Cirrhosis
  3. NCT03144700

The Natural History and Prognostic Factors of Compensated Cirrhosis.

Compensated Cirrhosis Clinical Trial

Official title:
The Natural History and Prognostic Factors of Compensated Cirrhosis: An Ambi Prospective Cohort Study

Clinical Trial Summary

Study Design and Methodology - Study Population:Compensated Cirrhosis - Study Design: An Ambi Prospective Cohort study - Study Period: 2 Years - Sample size: Retrospective- All patients from Jan 2010 to Mar 2017 Prospective- Assuming the incidence of clinical decompensation is 5%/year.With alpha of 5%, power 80% we need to enroll 138 cases. Further assuming 20% drop out 166 cases will be enrolled. - Intervention: This is an observational study. No intervention will be given. Monitoring and assessment: All the routine investigation and clinical information will be collected at 6, 12,18 and 24 months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03144700
Study type Observational
Source Institute of Liver and Biliary Sciences, India
Contact Dr Ankit Bhardwaj, Masters CR
Phone 01146300000
Email bhardwaj.ankit3@gmail.com
Status Recruiting
Phase
Start date January 1, 2010
Completion date January 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT02207088 - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Phase 3
Completed NCT02219503 - A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis Phase 3
Recruiting NCT04950764 - An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) Phase 1
Completed NCT05485714 - Non-invasive Prediction of Esophageal Varices in Patients With Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis
Enrolling by invitation NCT04160897 - Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
Completed NCT01704755 - A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis Phase 3
Completed NCT01409356 - Effects of Weight Loss on Portal Pressure in Patients With Overweight/Obesity and Cirrhosis Phase 2
Terminated NCT04060147 - Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis Phase 1
Active, not recruiting NCT03749954 - Detachable String Magnetically Controlled Capsule Endoscopy for Detecting High-risk Varices in Compensated Cirrhosis
Completed NCT01995071 - A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) Phase 2
Not yet recruiting NCT02732405 - Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis Phase 3
Completed NCT04210245 - Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) Phase 2
Completed NCT05367596 - OPTIMIzing muScle Preservation in paTients wIth Cirrhosis N/A
Recruiting NCT03990753 - Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensated Cirrhosis (CHESS1901/APPHA1901)
Completed NCT00190385 - Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis Phase 3
Recruiting NCT04196998 - Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis N/A
Completed NCT02642432 - A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis Phase 3
Completed NCT03656068 - An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis Phase 2
Not yet recruiting NCT05357599 - The Use of Endoscopic Ultrasound-Guided Portal Pressure Measurements to Guide Beta-Blocker Therapy in Patients With Compensated Cirrhosis N/A
Not yet recruiting NCT06147518 - To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis N/A